Title of article
Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries
Author/Authors
Gregg W. Stone، نويسنده , , David A. Cox، نويسنده , , Joseph Babb، نويسنده , , Dean Nukta، نويسنده , , Luc Bilodeau، نويسنده , , Louis Cannon، نويسنده , , Thomas D. Stuckey، نويسنده , , James Hermiller، نويسنده , , Eric A. Cohen، نويسنده , , Reginald Low، نويسنده , , Steven R. Bailey، نويسنده , , Alexandra J. Lansky، نويسنده , , Richard E. Kuntz and for the X-TRACT Investigators، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2003
Pages
7
From page
2007
To page
2013
Abstract
Objectives
We sought to determine whether routine thrombectomy prior to stent implantation in diseased saphenous vein grafts (SVGs) and thrombus-containing native coronary arteries would reduce peri-procedural myonecrosis and subsequently enhance event-free survival.
Background
Percutaneous coronary intervention in diseased SVGs and thrombotic native coronary arteries is complicated by a high rate of peri-procedural myocardial infarction (MI). Thrombectomy prior to intervention may enhance the safety of intervention and improve early and late outcomes in these high-risk patients.
Methods
At 60 centers in the U.S. and Canada, 797 patients with 839 diseased SVGs or thrombus-containing native coronary arteries were prospectively randomized to stent implantation with versus without prior thrombectomy with the X-SIZER device (ev3, Plymouth, Minnesota).
Results
Peri-procedural MI occurred in 15.8% of patients assigned to the X-SIZER device compared with 16.6% of control patients (p = 0.77), although the rate of large MI (pre-specified as the development of new pathologic Q waves or creatine phosphokinase-MB isoenzyme elevation >8 × upper limits of normal) was reduced with X-SIZER device use from 9.6% to 5.5% (multivariate risk ratio 0.35 [95% confidence interval 0.18 to 0.66], p = 0.002). Major adverse cardiac events (cardiac death, MI, or repeat target vessel revascularization) occurred in 16.8% of X-SIZER patients versus 17.1% of control patients at 30 days (p = 0.92), and in 31.3% of X-SIZER patients versus 28.2% of control patients at 1 year (p = 0.35).
Conclusions
Thrombectomy with the X-SIZER device prior to stent implantation in high-risk diseased SVGs and thrombus-containing native coronary arteries may reduce the extent, but not the occurrence, of myonecrosis. Early and late event-free survival, however, were not improved by routine thrombectomy with this device.
Keywords
Thrombolysis In Myocardial Infarction , TVR , CPK , ULN , target vessel revascularization , creatine phosphokinase , upper limit of normal , GP , X-TRACT , major adverse cardiac events , Glycoprotein , X-SIZER for Treatment of Thrombus and Atherosclerosis in Coronary Interventions Trial , MI , PCI , Percutaneous coronary intervention , SVG , mace , myocardial infarction , TIMI , saphenous vein graft
Journal title
JACC (Journal of the American College of Cardiology)
Serial Year
2003
Journal title
JACC (Journal of the American College of Cardiology)
Record number
598443
Link To Document